News Article

  1. You are here:    Home
  2. ...in the news
  3. News Article
BetaStem Therapeutics Retains Conditas Biotechnology Group for Business Development and Corporate Strategy
Date: Jul 18, 2013
Source: Business Wire ( click here to go to the source)
Featured firm in this article: BetaStem Therapeutics Inc of Sausalito, CA



SAN FRANCISCO--(BUSINESS WIRE)--BetaStem Therapeutics, Inc., a pre-clinical biotechnology company focused on a curative treatment for diabetic retinopathy and diseases related to vascular damage, has retained Conditas Biotechnology Group, LLC for its services in the area of business development and corporate strategy.

  Recent News

11132023
Selecta Biosciences Announces Merger with Cartesian Therapeutics
  Cartesian Therapeutics Inc (3 awards)
09252023
AcuraStem Enters into a License Agreement with Takeda to Advance PIKFYVE Therapeutics
  AcuraStem Inc (5 awards)
08222023
Grander Closes Acquisition of PolarityTE, Inc. Assets
  PolarityTE Inc (1 awards)
08082023
Arcfield Acquires Strategic Technology Consulting
  Strategic Technology Consulting LLC (1 awards)
08082023
Alchemist Completes Acquisition of Aqueous Resources LLC, a Leader in Industrial Brine Pre-Treatment Solutions and Direct Lithium Extraction
  Aqueous Resources LLC (1 awards)
08072023
Xenesis to send optical terminal to ISS platform
  Xenesis Inc (2 awards)
07202023
Advanced Sustainable Aviation Fuels Gain Momentum as AIR COMPANY Announces Collaboration with Air Canada
  Air Company Holdings Inc (2 awards)
07182023
Durham-based Novan Inc. sells all assets, files for bankruptcy
  Novan Inc (8 awards)
07172023
Novartis Acquires DTx Pharma in Potential $1B Deal
  DTx Pharma LLC (5 awards)
05312023
Adaract Awarded $400,000 from AngelNV and State Small Business Initiative (SSBCI)
  ADARACT (1 awards)